ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab ...Middle East

Amyloid-targeting drugs make up one part of the biology of aging approach and are the first step in developing multiple drugs to treat Alzheimer's disease NEW YORK, May 3, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported...

Hence then, the article about addf statement on topline results from phase 3 trial of amyloid clearing drug donanemab was published today ( Thursday 04/05/2023 - 12:40 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab )

Also on site :

• Police respond to incident at property in Dudley as residents 'spot armed police' in street
• Sinkhole on East Franklin Street Closes Lanes; Chapel Hill Urges for Detours
• Fire crews and Hazmat teams responded to fire involving lithium ion batteries at Higuera Street facility